STAT+: One of the most consequential years for cancer treatment, ever
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna announced success with their personalized mRNA cancer therapy in a melanoma late-stage clinical trial, announced the day before this article
- Revolution Medicines had success with a KRAS-targeted drug earlier in spring 2026, cited as the first of the year's landmark oncology results
- The personalized mRNA cancer therapy is characterized as an mRNA neoantigen vaccine in the author's social media post
- Author Adam Feuerstein framed 2026 as "one of the most consequential years in cancer treatment, ever" based on the two breakthroughs
- The story originally appeared in Adam's Biotech Scorecard, a STAT+ subscriber-only newsletter
- The article body beyond the introductory commentary is gated behind a STAT+ paywall
Why it matters: Two distinct oncology platforms — an mRNA neoantigen vaccine from Merck/Moderna and a KRAS-targeted drug from Revolution Medicines — both produced notable results within months, giving melanoma and KRAS-driven cancer patients two parallel avenues of late-stage clinical progress in a single calendar year.
Ask SkimNews
